
Lindsey T Brinton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10501910/publications.pdf Version: 2024-02-01



LINDSEV T RRINTON

| # | Article | IF | CITATIONS |
|---|--|------|-----------|
| 1 | Formation and role of exosomes in cancer. Cellular and Molecular Life Sciences, 2015, 72, 659-671. | 5.4 | 203 |
| 2 | Development of target-specific liposomes for delivering small molecule drugs after reperfused myocardial infarction. Journal of Controlled Release, 2015, 220, 556-567. | 9.9 | 50 |
| 3 | Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia. Journal of Hematology and Oncology, 2020, 13, 139. | 17.0 | 39 |
| 4 | PHASTpep: Analysis Software for Discovery of Cell-Selective Peptides via Phage Display and Next-Generation Sequencing. PLoS ONE, 2016, 11, e0155244. | 2.5 | 33 |
| 5 | Gilteritinib Inhibits Glutamine Uptake and Utilization in <i>FLT3</i> -ITD–Positive AML. Molecular Cancer Therapeutics, 2021, 20, 2207-2217. | 4.1 | 27 |
| 6 | Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition. Clinical Cancer Research, 2021, 27, 2352-2366. | 7.0 | 15 |
| 7 | TP-0903 is active in models of drug-resistant acute myeloid leukemia. JCl Insight, 2020, 5, . | 5.0 | 14 |
| 8 | Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia. Cancers, 2020, 12, 1574. | 3.7 | 10 |